Table 2 |
||||
|
Estimated Reporting Rate of All Malignancies and Lymphoma per 100 Patient-years (PY) of Etanercept Exposure |
||||
|
4-17 years |
18-22 years |
|||
|
|
||||
|
Worldwide |
US |
Worldwide |
US |
|
|
|
||||
|
Estimated exposure to etanercept (PY) through July 2009 |
49,716 |
33,409 |
33,887 |
22,349 |
|
|
||||
|
All malignancies (rate/100 PY) |
0.020 |
0.015 |
0.024* |
0.013* |
|
|
||||
|
Lymphoma (rate/100 PY) |
0.010 |
0.009 |
0.006* |
0.004* |
|
|
||||
|
*Calculated reporting rate for those age 18-22 years includes only cases with exposure prior to age 19 and does not includes cases with first etanercept exposure at age 19-22. |
||||
|
McCroskery et al. Pediatric Rheumatology 2010 8:18 doi:10.1186/1546-0096-8-18 |
||||
